# Suberoylanilide Hydroxamic Acid in Treating Patients With Metastatic and/or Locally Advanced or Locally Recurrent Thyroid Cancer

> **NCT00134043** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 19 (actual)

## Conditions studied

- Insular Thyroid Cancer
- Recurrent Thyroid Cancer
- Stage II Follicular Thyroid Cancer
- Stage II Papillary Thyroid Cancer
- Stage IV Follicular Thyroid Cancer
- Stage IV Papillary Thyroid Cancer
- Thyroid Gland Medullary Carcinoma

## Interventions

- **DRUG:** vorinostat

## Key facts

- **NCT ID:** NCT00134043
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-12
- **Primary completion:** 2009-03
- **Final completion:** 2009-03
- **Target enrollment:** 19 (ACTUAL)
- **Last updated:** 2014-08-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00134043

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00134043, "Suberoylanilide Hydroxamic Acid in Treating Patients With Metastatic and/or Locally Advanced or Locally Recurrent Thyroid Cancer". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00134043. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*